Condition
Grade III Glioma
Total Trials
4
Recruiting
3
Active
4
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
Early P 1 (1)
P 1 (1)
Trial Status
Recruiting3
Active Not Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07675070Recruiting
Safety and Effectiveness Evaluation of Temozolomide (Amitzo, NanoAlvand) in Patients With Grade III and IV Glioma Tumors
NCT04323046Phase 1Active Not Recruiting
Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults
NCT04135807Early Phase 1Recruiting
Implantable Microdevice In Primary Brain Tumors
NCT06975332Not ApplicableRecruiting
Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) in Glioma (WHO G3-G4) Progression
Showing all 4 trials